Washington, April 23 (ANI): A team of British scientists has created chemicals that have the potential to kill the most deadly malaria-causing parasite, Plasmodium falciparum - including those resistant to existing drugs.
Researchers at the University of Leeds say that the compounds work by preventing the enzyme dihydroorotate dehydrogenase (DHODH) - essential to the growth of the parasite - from working, which results in its death.
"Without this enzyme, Plasmodium falciparum is unable to grow and therefore it dies. The inhibitors developed at Leeds bind to the DHODH enzyme in the parasite and stop it functioning, preventing the proliferation of the parasites, which live in red blood cells. In addition, our chemicals are equally effective against parasites that have developed resistance to drugs," lead author Dr Glenn McConkey, from Leeds' Faculty of Biological Sciences, said.
"DHODH in humans is not an essential enzyme, so by concentrating our studies on it we can develop chemical inhibitors that have a negative impact on the parasite without any major side-effects to the human host. In effect we are exploiting a biological difference, and this will allow us to develop potent, selective inhibitors.
"Our chemicals are particularly exciting as they kill malaria parasites at low concentrations, something that is important for medicines as they are massively diluted on entering the bloodstream and, unlike many pharmaceutical products, we have a firm understanding of the molecular basis of their action. This project highlights the benefits of combining biological and chemistry disciplines," McConkey added.
Dr McConkey said the next step is to develop a larger collection of potent inhibitors and to see how these chemicals work alongside commonly used treatments.
"The parasites responsible for malaria have been very effective at developing resistance to existing drugs and efforts to find replacements are often stymied by the rate of resistance. Therefore it is essential that new products work effectively in combination with those already on the market," he said.
The research is published in the latest edition of the Journal of Medicinal Chemistry. (ANI)
Researchers at the University of Leeds say that the compounds work by preventing the enzyme dihydroorotate dehydrogenase (DHODH) - essential to the growth of the parasite - from working, which results in its death.
"Without this enzyme, Plasmodium falciparum is unable to grow and therefore it dies. The inhibitors developed at Leeds bind to the DHODH enzyme in the parasite and stop it functioning, preventing the proliferation of the parasites, which live in red blood cells. In addition, our chemicals are equally effective against parasites that have developed resistance to drugs," lead author Dr Glenn McConkey, from Leeds' Faculty of Biological Sciences, said.
"DHODH in humans is not an essential enzyme, so by concentrating our studies on it we can develop chemical inhibitors that have a negative impact on the parasite without any major side-effects to the human host. In effect we are exploiting a biological difference, and this will allow us to develop potent, selective inhibitors.
"Our chemicals are particularly exciting as they kill malaria parasites at low concentrations, something that is important for medicines as they are massively diluted on entering the bloodstream and, unlike many pharmaceutical products, we have a firm understanding of the molecular basis of their action. This project highlights the benefits of combining biological and chemistry disciplines," McConkey added.
Dr McConkey said the next step is to develop a larger collection of potent inhibitors and to see how these chemicals work alongside commonly used treatments.
"The parasites responsible for malaria have been very effective at developing resistance to existing drugs and efforts to find replacements are often stymied by the rate of resistance. Therefore it is essential that new products work effectively in combination with those already on the market," he said.
The research is published in the latest edition of the Journal of Medicinal Chemistry. (ANI)
Oneindia Login